PBAC's latest decision on Carfilzomib: Recommended with restriction (2022). Considered for Treatment of relapsed or refractory multiple myeloma (RRMM) after at least one prior therapy, in combination with lenalidomide and dexamethasone.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
6
first 2016
Submissions
6
2016 → 2022
Eligible population
Adults with relapsed or refractory multiple myeloma who have received at least one prior therapy, receiving carfilzomib in combination with lenalidomide and dexamethasone.
Therapy area
Oncology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
PFS
Key trials
ASPIRE, ENDEAVOR, ARROW, ELOQUENT-2, OPTIMISMM
Comparator
carfilzomib in combination with dexamethasone (Cd)
Economic model
Cost-minimisation
ICER note
Cost-minimisation approach used; no ICER calculated by design.
Risk sharing
Risk-sharing arrangement in place — Special Pricing Arrangements apply; Section 100 (Efficient Funding of Chemotherapy) listing with streamlined Authority Required restrictions.
Submission history
Nov 2016: Recommended with restriction · Authority Required
Jul 2017: Recommended with restriction · Authority Required
Mar 2018: Recommended · Restricted
Nov 2018: Not recommended · Restricted
Jul 2020: Recommended with restriction · Authority Required
Mar 2022: Recommended with restriction · Authority Required